Regenxbio Inc. has announced the publication of preclinical results demonstrating the functional benefits of their investigational gene therapy, RGX-202, for Duchenne Muscular Dystrophy. The study compared a microdystrophin construct that includes the C-terminal (CT) domain to one without it. Findings indicate that the inclusion of the CT domain leads to higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage. These results support the positive functional data observed in the Phase I/II AFFINITY DUCHENNE trial of RGX-202, which is the only gene therapy candidate for Duchenne that includes the CT domain. Interim results from this trial show promising changes in disease trajectory and a favorable safety profile. Regenxbio is currently enrolling participants in the pivotal portion of the AFFINITY DUCHENNE trial and plans to submit a Biologics License Application in mid-2026.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。